Comparative Pharmacology
Head-to-head clinical analysis: EMETE CON versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMETE CON versus TORECAN.
EMETE-CON vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antiemetic; dopaminergic antagonist at D2 receptors in the chemoreceptor trigger zone; also exhibits anticholinergic and antihistaminic properties.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
12.5 mg intravenously over 30 seconds as a single dose; may repeat once after 1 hour if necessary.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal and hepatic function; may extend to 15-20 hours in elderly or patients with hepatic impairment.
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Primarily hepatic metabolism (CYP2D6, CYP3A4) with <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 60-70% of metabolites, with renal elimination of metabolites constituting 25-35%.
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category C
Category C
Antiemetic
Antiemetic